AZN

Astrazeneca (AZN)

Company name:Astrazeneca Plc
Company Description:A group engaged in R&D; manufacture & marketing of prescription pharmaceuticals & biological products for healthcare areas such as cardiovascular; neuroscience; oncology; respiratory & inflammation
EPIC:AZNTrading Currency:GBX
Market Sector:FE10ISIN:GB0009895292
Market Segment:SET1Share Type:DE
WWW Address:http://www.astrazeneca.com/Description:ORD SHS $0.25
Industry Sector:PHARMACEUTICALS & BIOTECHNOLOGY
 Price Price Change [%] Bid Ask Open High Low Volume
 8,277.00 images.advfn.com/imagesnew/2/us/up 11.0 [0.13] 8,276.00 8,278.00 8,250.00 8,399.00 8,142.00 3,004,710
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 128,220.34 1,549.12 -2.19 175.77 204.80 47.09 2.47 8,923.00 - 6,736.00

Astrazeneca Key Figures

(at previous day's close)
Market Cap.128,220.34m
Shares In Issue1,549.12m
Prev. Close8,266.00
PE Ratio47.09 
Dividend Yield2.47%
EPS - basic175.77p
Dividend PS204.80p
Dividend Cover- 
Cash Flow PS226.59p
Return On Equity (ROE)20.46%
Operating Margin14.71%
PEG Factor0.34 
EPS Growth Rate136.89%
Dividends PS Growth Rate-%
Net Debt31,640.46m
Gross Gearing76.56%
Quick Assets14,171.98m
Net Working Capital2,262.28m
Intangibles / Fixed Assets77.22%
Turnover PS1,256.73p
Pre-Tax Profit PS184.89p
Retained Profit PS-17.75p
Cash PS369.79p
Net Cash PS-589.01p
Net Tangible Asset Value PS *-842.13p
Net Asset Value PS738.35p
Spread2.00 (0.02%) 

Astrazeneca Balance Sheet

L^AZN:Liabilities+EQL^AZN:Assets

Share Price Performance

Sample Period HighLow
1 week8,525.008,142.00
4 weeks8,810.008,142.00
12 weeks8,810.007,556.00
1 year8,923.006,736.00

Share Price Chart (5 years)

Astrazeneca Historic Returns

Giorni da oggi OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week8,483.00-206.00-2.438,142.002.288,345.38
4 weeks8,700.00-423.00-4.868,142.004.318,482.51
12 weeks7,699.00578.007.517,556.002.878,313.62
26 weeks7,486.00791.0010.576,736.002.847,745.66
1 year8,707.00-430.00-4.946,736.002.507,868.00
3 years5,699.002,578.0045.245,312.002.397,188.17
5 years5,000.003,277.0065.543,996.002.426,233.36

Astrazeneca Key Management Ratios

Astrazeneca Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio121.42 
PE Ratio47.09 
Tobin's Q Ratio 2.00 
Tobin's Q Ratio (excl. intangibles)4.17 
Dividend Yield2.47%
Market-to-Book Ratio11.22 
Price-to-Pre-Tax Profit PS44.77 
Price-to-Retained Profit PS-466.23 
Price-to-Cash Flow PS36.53 
Price-to-Sales PS6.59 
Price-to-Net Tangible Asset Value PS-9.84 
Price-to-Cash PS22.38 
Net Working Capital PS146.04 
Price Pct to Working Capital PS56.68%
Earnings Yield2.12%
Average PE35.20 
Years in average5 
PE to PE average133.78%

Astrazeneca Financial Ratios

(Leverage Ratios)
Debt Ratio66.31%
Debt-to-Equity Ratio1.97 
Debt-to-Equity Ratio (excl. Intgbl)-1.73 
Debt-to-Equity Market Value0.18 
Net Gearing64.83%
Net Gearing (excl. Intangibles)130.02%
Gross Gearing76.56%
Gross Gearing (excl. Intangibles)153.56%
Gearing Under 1 Year30.43%
Gearing Under 1 Year (excl. Intgbl)61.04%
Assets/Equity4.27 
Cash/Equity50.08 
(Liquidity Ratios)
Net Working Capital to Total Assets4.64%
Current Ratio1.15 
Quick Ratio (Acid Test)0.95 
Liquidity Ratio0.39 
Cash & Equiv/Current Assets33.47%
(Solvency Ratios)
Enterprise Value145,019.58m
CFO/Sales0.18 
CFO/Attributable Profit1.50 
CFO/Assets0.07 
CFO/Debt0.09 
Total Debt/Equity Market Value0.29 
Total Debt/Sales1.92 
Total Debt/Pre-Tax Profit13.05 
Total Debt37,368.94m
Total Debt/Net Current Assets16.52%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth12.80%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs9 
Beta (60-Mnth)Beta (36-Mnth)
-2.1862-1.3705

Astrazeneca Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)8.44%
Return On Assets (ROA)3.65%
Net Profit Margin12.01%
Assets Turnover0.30 
Return On Equity (ROE)20.46%
Return On Investment (ROI)5.21%
Dividend Payout Ratio114.75%
Plowback Ratio-14.75%
Growth from Plowback Ratio-2.40%
Net Income Of Revenues-1.41%
(Asset Utilisation Multiples)
Shareholders Equity Turnover1.35 
Fixed Assets Turnover0.45 
Current Assets Turnover0.94 
Net Working Capital Turnover 
Inventory Turnover5.40 
(Other Operating Ratios)
Total Assets-to-Sales3.29 
Debtors-to-Sales54.06%
Debt Collection Period197.31Days

Astrazeneca Dividends

Announcement DateTypeCurr.Dividend AmountPeriod StartPeriod EndEx DateRecord DatePayment DateTotal Dividend Amount
29 Jul 2021InterimUSX90.0012/31/202012/31/202108/12/202108/13/202109/13/2021-
16 Feb 2021InterimUSX190.0012/31/201912/31/202002/25/202102/26/202103/29/2021280.00
30 Jul 2020InterimUSX90.0012/31/201912/31/202008/13/202008/14/202009/14/2020-
14 Feb 2020InterimUSX190.0012/31/201812/31/201902/27/202002/28/202003/30/2020280.00
25 Jul 2019InterimUSX90.0012/31/201812/31/201908/08/201908/09/201909/09/2019-
14 Feb 2019FinalUSX190.0012/31/201712/31/201802/28/201903/01/201903/27/2019280.00
26 Jul 2018InterimUSX90.0012/31/201712/31/201808/09/201808/10/201809/10/2018-
02 Feb 2018FinalUSX190.0012/31/201612/31/201702/15/201802/16/201803/19/2018280.00
27 Jul 2017InterimUSX90.0012/31/201612/31/201708/10/201708/11/201709/11/2017-
02 Feb 2017FinalUSX190.0012/31/201512/31/201602/16/201702/17/201703/20/2017280.00
28 Jul 2016InterimUSX90.0012/31/201512/31/201608/11/201608/12/201609/12/2016-
04 Feb 2016FinalUSX190.0012/31/201412/31/201502/18/201602/19/201603/21/2016280.00
30 Jul 2015InterimUSX90.0012/31/201412/31/201508/13/201508/14/201509/14/2015-
05 Feb 2015FinalUSX190.0012/31/201312/31/201402/19/201502/20/201503/23/2015280.00
31 Jul 2014InterimUSX90.0012/31/201312/31/201408/13/201408/15/201409/15/2014-
06 Feb 2014FinalUSX190.0012/31/201212/31/201302/19/201402/21/201403/24/2014280.00
01 Aug 2013InterimUSX90.0012/31/201212/31/201308/14/201308/16/201309/16/2013-
31 Jan 2013FinalUSX190.0012/31/201112/31/201202/13/201302/15/201303/18/2013280.00
26 Jul 2012InterimUSX90.0012/31/201112/31/201208/08/201208/10/201209/10/2012-
02 Feb 2012FinalUSX195.0012/31/201012/31/201102/15/201202/17/201203/19/2012280.00
28 Jul 2011InterimUSX85.0012/31/201012/31/201108/03/201108/05/201109/12/2011-
27 Jan 2011FinalUSX185.0012/31/200912/31/201002/02/201102/04/201103/14/2011255.00
29 Jul 2010InterimUSX70.0012/31/200912/31/201008/02/201008/04/201009/13/2010-
28 Jan 2010FinalUSX171.0012/31/200812/31/200902/03/201002/05/201003/15/2010230.00
30 Jul 2009InterimUSX59.0012/30/200806/30/200908/05/200908/07/200909/14/2009-
29 Jan 2009FinalUSX150.0012/31/200712/31/200802/04/200902/06/200903/16/2009205.00
31 Jul 2008InterimUSX55.0012/30/200706/30/200808/08/200808/06/200809/15/2008-
31 Jan 2008FinalUSX135.0012/31/200612/31/200702/06/200802/08/200803/17/2008187.00
26 Jul 2007InterimUSX52.0006/30/200606/30/200708/08/200708/10/200709/17/2007-
01 Feb 2007FinalUSX123.0012/31/200512/31/200602/07/200702/09/200703/19/2007172.00
27 Jul 2006InterimUSX49.0012/30/200506/30/200608/09/200608/11/200609/18/2006-
01 Feb 2006FinalUSX92.0012/31/200412/31/200502/08/200602/10/200603/20/2006130.00
29 Jul 2005InterimUSX38.0012/30/200406/30/200508/10/200508/12/200509/19/2005-
27 Jan 2005FinalUSX64.5012/31/200312/31/200402/09/200502/11/200503/21/200594.00
22 Jul 2004InterimUSX29.5012/30/200306/30/200408/11/200408/13/200409/20/2004-
29 Jan 2004FinalUSX54.0012/31/200212/31/200302/18/200402/20/200404/06/200479.50
24 Jul 2003InterimUSX25.5012/30/200206/30/200308/20/200308/22/200310/06/2003-
30 Jan 2003FinalUSX47.0012/31/200112/31/200202/19/200302/21/200304/07/200370.00
25 Jul 2002InterimUSX23.0012/30/200106/30/200208/21/200208/23/200210/07/2002-
31 Jan 2002FinalUSX47.0012/31/200012/31/200102/20/200202/22/200204/08/200270.00
26 Jul 2001InterimUSX23.0012/30/200006/30/200108/22/200108/24/200110/05/2001-
08 Feb 2001FinalUSX47.0012/31/199912/31/200002/21/200102/23/200104/09/200170.00
01 Aug 2000InterimUSX23.0012/30/199906/30/200009/04/200009/08/200010/23/2000-
24 Feb 2000FinalUSX47.0012/31/199812/31/199903/06/200003/10/200004/17/200070.00
03 Aug 1999InterimUSX23.0012/30/199806/30/199909/06/199909/10/199910/25/1999-

Astrazeneca Fundamentals

 31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)31 Dec 2020 (USD)
turnover22,465.00100.00%22,090.00100.00%24,384.00100.00%26,617.00100.00%m
pre tax profit2,227.009.91%1,993.009.02%1,548.006.35%3,916.0014.71%m
attributable profit3,001.0013.36%2,155.009.76%1,335.005.47%3,196.0012.01%m
retained profit-518.00-2.31%-1,329.00-6.02%-2,257.00-9.26%-376.00-1.41%m
eps - basic237.00 170.00 103.00 244.00 
eps - diluted237.00 170.00 103.00 244.00 
dividends per share280.00 280.00 280.00 280.00 

Astrazeneca Balance Sheet

 31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)31 Dec 2020 (USD)
L^AZN:Liabilities+EQL^AZN:AssetsL^AZN:Liabilities+EQL^AZN:AssetsL^AZN:Liabilities+EQL^AZN:AssetsL^AZN:Liabilities+EQL^AZN:Assets
 31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)31 Dec 2020 (USD)
ASSETS
fixed assets fixed assets7,615.0012.02%7,421.0012.24%7,688.0012.53%8,251.0012.36%m
intangibles intangibles38,013.0060.00%33,666.0055.51%33,148.0054.01%33,458.0050.14%m
fixed investments fixed investments2,798.004.42%2,186.003.60%2,405.003.92%1,620.002.43%m
current assets - other current assets - other--%--%70.000.11%--%m
stocks stocks3,035.004.79%2,890.004.76%3,193.005.20%4,024.006.03%m
debtors debtors8,569.0013.53%9,657.0015.92%9,504.0015.48%11,544.0017.30%m
cash & securities cash & securities3,324.005.25%4,831.007.97%5,369.008.75%7,832.0011.74%m
TOTAL63,354.00100%60,651.00100%61,377.00100%66,729.00100%m
LIABILITIES
creditors - short creditors - short16,383.0025.86%16,292.0026.86%18,117.0029.52%20,307.0030.43%m
creditors - long creditors - long30,329.0047.87%30,315.0049.98%28,664.0046.70%30,784.0046.13%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
TOTAL46,712.0073.73%46,607.0076.84%46,781.0076.22%51,091.0076.56%m
EQUITY
ord cap, reserves ord cap, reserves14,960.0023.61%12,468.0020.56%13,127.0021.39%15,622.0023.41%m
prefs, minorities prefs, minorities1,682.002.65%1,576.002.60%1,469.002.39%16.000.02%m
TOTAL16,642.0026.27%14,044.0023.16%14,596.0023.78%15,638.0023.44%m
OTHER
NAV Basic- - - - 
NAV Diluted- - - - 

Astrazeneca Cash Flow Statement

31 Dec 2017 (USD)31 Dec 2018 (USD)31 Dec 2019 (USD)31 Dec 2020 (USD)
Operating CF3,578.002,618.002,969.004,799.00m
Pre-Financing CF1,250.003,581.002,312.004,514.00m
Retained CF-1,686.001,537.00547.002,311.00m

Astrazeneca Brokers

NameActivityTypeMnemonicCode
Evolution Securities LimitedMarket Maker(MME)Broker/DealerEVOEVBGGB21MMT
Nyenburgh Holding B.V.Market Maker(MME)Broker/DealerNYBBNYENNL2B
Winterflood Securities LtdMarket Maker(MME)Broker/DealerWINSWNTSGB2LBIC
Your Recent History
LSE
AZN
Astrazenec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:us D:20210729 19:31:29